Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seletracetam

Drug Profile

Seletracetam

Alternative Names: UCB 44212

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Oct 2006 Interim results from two phase IIa clinical trials (N01191 and N01192) in patients with epilepsy have been added to the adverse events and Epilepsy therapeutic trials sections
  • 21 Nov 2005 Data presented at the 26th International Epilepsy Congress (IEC-2005) have been added to the Epilepsy and seizure disorders pharmacodynamics section ,,
  • 18 Apr 2005 Data presented at the 9th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2005) have been added to the Parkinson's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top